Cicero Diagnostics is currently involved with additional research studies having been awarded an SBIR Fast Track grant from the NIH in January of 2019. This 3 year grant allows Cicero to continue to validate what has currently been published on the biomarkers' value in predicting endometriosis as the source of a women's unexplained infertility. Other published papers have demonstrated the success of follow-up treatment leading to more live births for previously failed IVF patients. Using Wake Forest Medical Center, University of North Carolina, Clemson University and Stanford University, Cicero Diagnostics will conduct additional studies to supplement and support these findings.

Website: cicerodx.com

Phone: (800) 795-5385